Transcript Title Here

PatientBase™…..
(Decision Resources’ Customizable
Epidemiology Database)
DECISION RESOURCES
Knowledge, Experience, Insight
© Decision Resources, Inc., 2005
Company Confidential
 PatientBase™
Features
Methodology
 Demonstration
 Applications / Uses
 Appendix
2
DECISION RESOURCES >
PatientBase™
DECISION RESOURCES
Knowledge, Experience, Insight
Company Confidential
What is PatientBase™
> Online database of 103 diseases and 153 indications
> Therapeutic Coverage
1. Cancer
2. Cardiovascular
3. CNS
4. Immune & Inflammatory
5. Infectious
6. High Interest Diseases like Obesity,
Osteoporosis, Erectile Dysfunction etc.
> Geographic Focus
 United States
 Japan
 France, Germany, Italy, Spain and United Kingdom
> Frequency of Outputs
 Released quarterly with most indications updated annually
> Created, analyzed and validated by DR’s wellcredentialed Epidemiology staff
4
DECISION RESOURCES >
Company Confidential
PatientBase™ Features
> 10 year forecast – 2004 to 2014
 Prevalent cases / Incident cases
 Diagnosed
 Drug treated
 Five-year age cohorts
 By gender
 Types of sub-population (Co-morbidity, Severity,
Seasonality etc.)
 Corresponding UN population
> Data portability into Excel
> Complete access to Sources & Methodology behind
the data
5
DECISION RESOURCES >
Company Confidential
PatientBase™ Development Methodology
> Epidemiologists conduct exhaustive secondary literature
searches
 Several hundred studies are reviewed for each indication
 If appropriate, analyses of primary data sources are conducted
> Epidemiologists choose the best country-specific populationbased studies
 Size and representativeness of subject population and rigor of
case ascertainment methods
> Academic epidemiological methods are applied in conducting
analyses to determine methodology
> Age- and gender-specific incidence or prevalence is applied to
age- and gender-specific United Nations population estimates
 For each country to reflect influence of demographic changes over
time on patient populations
6
DECISION RESOURCES >
Company Confidential
Epidemiology Data Sources
DR’s expert epidemiologists consult primary data sources, team with expert
reviewers, and review hundreds of secondary data sources for estimating
incidence/prevalence trends
Bundes-Gesundheitssurvey 98
7
ECA
DECISION RESOURCES >
PatientBase™ - Demonstration
DECISION RESOURCES
Knowledge, Experience, Insight
Company Confidential
PatientBase™ – Demonstration (First Page)
Begin by selecting
an indication (Up to 16
indications at one time)
Click to go to the
Epi Query page
9
DECISION RESOURCES >
Company Confidential
PatientBase™ – Demonstration (Epi Query)
10
DECISION RESOURCES >
Company Confidential
PatientBase™ – Demonstration (Epi Query)
Step 1
11
DECISION RESOURCES >
Company Confidential
PatientBase™ – Demonstration (Epi Query)
Subpopulation is the distribution of
Step 2
Prevalent/Incident cases specific to
an Indication
provided for more than half of
all diseases and conditions
Co-morbidity
Severity
Laboratory measure
Seasonality
Etiology
Pathogen type
Infection site
Treatment type
12
DECISION RESOURCES >
Company Confidential
PatientBase™ – Demonstration (Epi Query)
Step 3
Prevalent cases: all patients with the
disease/condition at a point in time
Incident cases: all patients newly
diagnosed with the disease/condition
Drug-treated cases: all diagnosed patients
who are receiving pharmacotherapy
Corresponding U.N. population data: the
total number of United Nations-estimated
people in the population that corresponds to
the cases of people with the disease or
condition
13
DECISION RESOURCES >
Company Confidential
PatientBase™ – Demonstration (Epi Query)
Step 4
•Regional total: total regional patient
populations (United States, Europe,
Japan)
•Country total: total country patient
populations (United States, France,
Germany, Italy, Spain, the United Kingdom,
and Japan)
•Country and gender detail: breakout of
country-specific patient populations by
male and female
•Country, gender, and age detail: breakout
of country-specific patient populations by
male and female and by 5-year age
breakouts
14
DECISION RESOURCES >
Company Confidential
PatientBase™ – Demonstration (Epi Query)
Step 5
> Formatted table: data are presented in
attractive table for ease of use and
presentation
> Raw data spreadsheet: data are presented in
raw table which is easiest to manipulate
when exported to Excel
> Both formats can be exported to Excel for
further manipulation
> Forecast period: forecast is presented in 5
year increments
 2004
2009
2014
> Client can choose to view annualized
forecasts through 2014 or forecasts of
individual years
15
DECISION RESOURCES >
Company Confidential
PatientBase™ – Demonstration (Epi Results)
16
DECISION RESOURCES >
Company Confidential
PatientBase™ – Demonstration (Epi Results)
Tool Bar
•Methodology: thorough and transparent discussions of overall and
country-specific methodologies used to obtain patient population
estimates and subpopulations
•Bibliography: complete bibliography of all sources analyzed for the
methodology
•Key Sources: country-specific list of primary sources used to
estimate key patient populations and subpopulations
17
DECISION RESOURCES >
Company Confidential
PatientBase™ – Application / Uses
> Estimate the number of people with drug-treatable
disease or condition over time
 Percent diagnosed
 Percent treated
> Segment cases by age, gender, stage, severity,
genetic factor, disease attribute, co-morbidity or
country
> Annualized population forecasts
> Compare populations across Indications
18
DECISION RESOURCES >
Company Confidential
Support & Services
> DR’s highly skilled Epidemiology staff will answer
any questions regarding PatientBase™
 Staff members with over 50 years combined work
experience
> DR’s Consulting Group along with Epidemiology
staff can assist in any customized Epidemiology
work
 Additional Indications
 Geography not covered in PatientBase™
19
DECISION RESOURCES >
Company Confidential
Appendix
Oncology Indications in PatientBase™
- For U.S.A, Japan & Europe (France, Germany, Italy,
Spain, U.K.)
>
>
>
>
>
>
>
>
>
>
>
>
>
20
Acute Myeloid Leukemia
Bladder Cancer-Superficial
Bladder Cancer-Metastatic
Bladder Cancer-Muscle-Invasive
Breast Cancer-Stage I
Breast Cancer-Stage II
Breast Cancer-Stage III
Breast Cancer-Stage IV
Cervical Cancer-Stage I
Cervical Cancer-Stage III
Cervical Cancer-Stage III
Cervical Cancer-Stage IV
Chronic Lymphocytic LeukemiaHigh Risk
>
>
>
>
>
>
>
>
>
>
>
Chronic Lymphocytic LeukemiaIntermed. Risk
Chronic Lymphocytic LeukemiaLow Risk
Chronic Myelogenous Leukemia
Colon Cancer-Stage I
Colon Cancer-Stage II
Colon Cancer-Stage III
Colon Cancer-Stage IV
Colorectal Cancer-Stage I
Colorectal Cancer-Stage II
Colorectal Cancer-Stage
Colorectal Cancer-Stage IV
DECISION RESOURCES >
Company Confidential
Appendix
Oncology Indications in PatientBase™ Cont.
- For U.S.A, Japan & Europe (France, Germany, Italy,
Spain, U.K.)
>
>
>
>
>
>
>
>
>
>
>
>
>
21
Esophageal Cancer - Distant
Esophageal Cancer - Limited
Esophageal Cancer - Regional
Esophageal Cancer - Unknown
Glioma
Liver Cancer - Distant
Liver Cancer - Limited
Liver Cancer - Regional
Liver Cancer - Unknown
Malignant Melanoma-Stage I
Malignant Melanoma-Stage II
Malignant Melanoma-Stage III
Malignant Melanoma-Stage IV
>
>
>
>
>
>
>
>
>
>
>
>
>
Multiple Myeloma-Stage I
Multiple Myeloma-Stage II
Multiple Myeloma-Stage III
Non-Hodgkin's Lymphoma-Aggressive
Non-Hodgkin's Lymphoma-Indolent
Non-Small-Cell Lung Cancer-Stage I
Non-Small-Cell Lung Cancer-Stage II
Non-Small-Cell Lung Cancer-Stage III
Non-Small-Cell Lung Cancer-Stage IV
Ovarian Cancer-Stage I
Ovarian Cancer-Stage II
Ovarian Cancer-Stage III
Ovarian Cancer-Stage IV
DECISION RESOURCES >
Company Confidential
Appendix
Oncology Indications in PatientBase™ Cont.
- For U.S.A, Japan & Europe (France, Germany, Italy,
Spain, U.K.)
>
>
>
>
>
>
>
>
>
>
>
22
Pancreatic Cancer-Distant
Pancreatic Cancer-Localized
Pancreatic Cancer-Regional
Prostate Cancer-Stage I
Prostate Cancer-Stage II
Prostate Cancer-Stage III
Prostate Cancer-Stage IV
Rectal Cancer-Stage I
Rectal Cancer-Stage II
Rectal Cancer-Stage III
Rectal Cancer-Stage IV
>
>
>
>
>
>
>
>
>
Renal Cell Carcinoma-Stage I/II
Renal Cell Carcinoma-Stage III
Renal Cell Carcinoma-Stage IV
Small-Cell Lung Cancer-Extensive
Small-Cell Lung Cancer-Limited
Stomach Cancer - Distant
Stomach Cancer - Limited
Stomach Cancer - Regional
Stomach Cancer - Unknown
DECISION RESOURCES >
Company Confidential
Appendix
Central Nervous System Indications in PatientBase™
- For U.S.A, Japan & Europe (France, Germany, Italy,
Spain, U.K.)
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
Acute Ischemic Stroke
Alzheimer’s Disease
Attention-Deficit/Hyperactivity DisorderAdult
Attention-Deficit/Hyperactivity DisorderPediatric
Bipolar Disorder
Chronic Low Back Pain
Dementia
Epilepsy
Generalized Anxiety Disorder
Insomnia
Major Depression
Migraine (Prophylaxis)
Mild Cognitive Impairment
Minor Depression
Multiple Sclerosis (Chronic-Progressive)
23
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
Multiple Sclerosis (Relapsing-Remitting)
Narcolepsy
Obsessive-Compulsive Disorder
Obstructive Sleep Apnea
Osteoarthritic Pain
Panic Disorder
Parkinson’s Disease
Post-operative Pain
Restless Legs Syndrome
Rheumatoid Arthritic Pain
Schizophrenia
Social Anxiety Disorder
Postherpetic Neuralgia
Painful Diabetic Neuropathy
DECISION RPain
ESOURCES >
HIV-Related Neuropathic
Company Confidential
Appendix
Infectious Diseases Indications in PatientBase™
- For U.S.A, Japan & Europe (France, Germany, Italy,
Spain, U.K.)
>
>
>
>
>
>
>
>
>
>
>
24
Acute Exacerbations of Chronic Bronchitis
Community-Acquired Pneumonia
Hepatitis B
Hepatitis C
Herpes Zoster
HIV-Newly Diagnosed Population
Human Immunodeficiency Virus
Influenza A and B
Methicillin-Resistant Staph A
Sepsis
Complications of Soft Skin Tissue
Infection
DECISION RESOURCES >
Company Confidential
Appendix
Cardiovascular Indications in PatientBase™
- For U.S.A, Japan & Europe (France, Germany, Italy,
Spain, U.K.)
>
>
>
>
>
>
>
>
>
>
>
>
25
Acute Heart Failure
Acute Myocardial Infarction
Atrial Fibrillation
Chronic Heart Failure
Coronary Heart Disease
Dyslipidemia
Hypertension
Peripheral Arterial Disease
Post-Myocardial Infarction
Pulmonary Arterial Hypertension
Non-ST-Elevation Myocardial Infarction
Venous Thromboembolism
DECISION RESOURCES >
Company Confidential
Appendix
Immune and Inflammatory Disorders Indications in
PatientBase™
- For U.S.A, Japan & Europe (France, Germany, Italy,
Spain, U.K.)
>
>
>
>
>
>
>
>
26
Allergic Rhinitis
Asthma
Crohn’s Disease
Diabetic Nephropathy
Eczema/ Atopic Dermatitis
Metabolic Syndrome
Fibromyalgia
Osteoarthritis
>
>
>
>
>
>
>
Psoriasis
Rheumatoid Arthritis
Systemic Lupus Erythematosus
Type 1 Diabetes
Type 2 Diabetes
Ulcerative Colitis
Urticaria
DECISION RESOURCES >
Company Confidential
Appendix
High-Interest Disease in PatientBase™
- For U.S.A, Japan & Europe (France, Germany, Italy,
Spain, U.K.)
>
>
>
>
>
>
>
>
>
>
>
>
>
27
Age-Related Macular Degeneration (Wet)
Benign Prostatic Hyperplasia
Chronic Obstructive Pulmonary Disease
Diabetic Neuropathy
Diabetic Retinopathy
Erectile Dysfunction
Female Sexual Dysfunction
Gastroesophageal Reflux Disease
Irritable Bowel Syndrome
Obesity
Osteoporosis
Urinary Incontinence (Urge)
Urinary Incontinence (Stress)
DECISION RESOURCES >
Company Confidential
For Further Information
28
North America
Europe
Japan
Mr. Bob Fucile
Tel. 781-296-2500
Fax 781-296-2550
[email protected]
Decision Resources, Inc.
260 Charles Street
Waltham, MA 02453
Ms. Vera Bisegna
Tel. +32-2-351-10-79
Fax +32-2-351-23-47
[email protected]
Decision Resources International, Inc.
Avenue des Chasseurs, 1
1410 Waterloo, Belgium
Ms. Makiko Yoshimoto
Tel. +81-3-5401-2615
Fax +81-3-5401-2617
[email protected]
Decision Resources International, Inc.
Fukide Building F4
4-1-13 Toranomon
Minato-ku, Tokyo 105-0001 Japan
DECISION RESOURCES >